|Bid||48.00 x 5100|
|Ask||48.04 x 2800|
|Day's Range||47.62 - 48.27|
|52 Week Range||36.81 - 50.24|
|PE Ratio (TTM)||11.62|
|Dividend & Yield||1.64 (3.41%)|
|1y Target Est||N/A|
Merck and Co Inc said on Thursday the U.S. Food and Drug Administration (FDA) tentatively approved its biosimilar version of French drugmaker Sanofi SA's blockbuster diabetes treatment, Lantus. Merck's copycat, if launched, would challenge Lantus as a cheaper alternative that could chip away at the drug's sales, which reached 5.71 billion euros ($6.6 billion) last year and represented over a sixth of Sanofi's total sales.
Valeant (VRX) has decided to sell Obagi Medical for $190 million and use the proceeds for reducing down debt.
Novartis reported smaller earnings and revenue declines for Q2 than expected. Johnson & Johnson topped on earnings but fell just shy on revenue.